Non-Interventional Real-World European Study Quantifying The Burden Of Central Nervous System (CNS) Metastases On Healthcare Resource Use (HRU) In Patients With Metastatic Non-Small-Cell Lung Cancer (MNSCLC) – Results From An Interim Analysis

OBJECTIVES: Limited information is available regarding CNS metastases impact on HRU and HRQoL for patients with mNSCLC in Europe. This ongoing study (MO39084) compares HRQoL and HRU in mNSCLC patients with and without CNS metastases alongside demographic/clinical characteristics and concomitant medications. METHODS: Patients ≥18 years with mNSCLC, CNS metastases documented 2-8 months before inclusion visit (VI), and a life expectancy ≥12 weeks are eligible (31 sites Germany/France). Three study visits were planned: VI, follow-up visit (6±3 weeks after VI), final visit (12±3 weeks after VI). HRU data are collected via validated patient questionnaires and clinical charts. Student's T-test (continuous variables), chi-square test or Fisher's exact test (categorical variables) were used for group comparisons. RESULTS: At data cut-off (29 May 2017), 123 patients were eligible: CNS metastases cohort n=49 and non-CNS metastases cohort n=74. Baseline characteristics were similar between cohorts: mean age 63 vs 67 years; 53% vs 66% male; mean BMI 23.6 vs 24.9 kg/m2; ex-smoker status 51% vs 47%; mean time since diagnosis 6.1 vs 5.4 months; ECOG PS 1 55% vs 54%, and 1-2 chronic comorbidities 51% vs 49%. At VI, 41% (CNS metastases cohort) and 14% (non-CNS metastases cohort) had ≥3 metastatic sites (p=0.002). Dyspnoea (16% vs 31%, p=0.07), cough (14% vs 28%, p=0.07) and pain (12% vs 28%, p=0.03) were more common in the non-CNS metastases cohort. Similar HRU patterns were recorded in the cohorts before VI; no significant differences in number of hospitalizations (p=0.75), emergency room (p=0.22) or outpatient visits (p=0.22). Length of hospital stay was significantly longer in the CNS metastases cohort (p